RIP1/RIP3-regulated Necroptosis As a Target for Multifaceted Disease Therapy (Review)

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2019 Jun 15

PMID 31198981

Citations 78

Authors

Yuping Liu

Ting Liu

Tiantian Lei

Dingding Zhang

Suya Du

Lea Girani

Dandan Qi

Chen Lin

Rongsheng Tong

Yi Wang

Affiliations

Soon will be listed here.

Abstract

Necroptosis is a type of programmed cell death with necrotic morphology, occurring in a variety of biological processes, including inflammation, immune response, embryonic development and metabolic abnormalities. The current nomenclature defines necroptosis as cell death mediated by signal transduction from receptor‑interacting serine/threonine kinase (RIP) 1 to RIP3 (hereafter called RIP1/RIP3). However, RIP3‑dependent cell death would be a more precise definition of necroptosis. RIP3 is indispensable for necroptosis, while RIP1 is not consistently involved in the signal transduction. Notably, deletion of RIP1 even promotes RIP3‑mediated necroptosis under certain conditions. Necroptosis was previously thought as an alternate process of cell death in case of apoptosis inhibition. Currently, necroptosis is recognized to serve a pivotal role in regulating various physiological processes. Of note, it mediates a variety of human diseases, such as ischemic brain injury, immune system disorders and cancer. Targeting and inhibiting necroptosis, therefore, has the potential to be used for therapeutic purposes. To date, research has elucidated the suppression of RIP1/RIP3 via effective inhibitors and highlighted their potential application in disease therapy. The present review focused on the molecular mechanisms of RIP1/RIP3‑mediated necroptosis, explored the functions of RIP1/RIP3 in necroptosis, discussed their potential as a novel therapeutic target for disease therapy, and provided valuable suggestions for further study in this field.

Citing Articles

RIPK1 in necroptosis and recent progress in related pharmaceutics.

Yao K, Shi Z, Zhao F, Tan C, Zhang Y, Fan H Front Immunol. 2025; 16:1480027.

PMID: 40007541 PMC: 11850271. DOI: 10.3389/fimmu.2025.1480027.

Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model.

Tu X, Zou Z, Li J, Zeng S, Luo Z, Li G Chin Med J (Engl). 2024; 138(2):172-184.

PMID: 39719694 PMC: 11745860. DOI: 10.1097/CM9.0000000000003387.

Identification of key necroptosis-related genes and immune landscape in patients with immunoglobulin A nephropathy.

Hu R, Liu Z, Hou H, Li J, Yang M, Feng P BMC Nephrol. 2024; 25(1):459.

PMID: 39696012 PMC: 11653910. DOI: 10.1186/s12882-024-03885-4.

Involvement of necroptosıs and apoptosıs ın protectıve effects of cyclosporın a on ischemıa-reperfusıon injury in rat kıdney.

Ozgen Z, Erdinc M, Kaya M, Aktar F, Ozekinci S, Erdinc L J Mol Histol. 2024; 56(1):30.

PMID: 39630315 DOI: 10.1007/s10735-024-10281-7.

SPOP-mediated RIPK3 destabilization desensitizes LPS/sMAC/zVAD-induced necroptotic cell death.

Lee G, Bang G, Byun J, Chen W, Jeung D, Cho H Cell Mol Life Sci. 2024; 81(1):451.

PMID: 39540935 PMC: 11564579. DOI: 10.1007/s00018-024-05487-7.

References

Magnusson C, Vaux D . Signalling by CD95 and TNF receptors: not only life and death. Immunol Cell Biol. 1999; 77(1):41-6. DOI: 10.1046/j.1440-1711.1999.00800.x. View

Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y . Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999; 162(7):3749-52. View

Sun X, Lee J, Navas T, Baldwin D, Stewart T, Dixit V . RIP3, a novel apoptosis-inducing kinase. J Biol Chem. 1999; 274(24):16871-5. DOI: 10.1074/jbc.274.24.16871. View

Kawai T, Adachi O, Ogawa T, Takeda K, Akira S . Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 1999; 11(1):115-22. DOI: 10.1016/s1074-7613(00)80086-2. View

Lin Y, Devin A, Rodriguez Y, Liu Z . Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev. 1999; 13(19):2514-26. PMC: 317073. DOI: 10.1101/gad.13.19.2514. View

Kasof G, Prosser J, Liu D, Lorenzi M, Gomes B . The RIP-like kinase, RIP3, induces apoptosis and NF-kappaB nuclear translocation and localizes to mitochondria. FEBS Lett. 2000; 473(3):285-91. DOI: 10.1016/s0014-5793(00)01473-3. View

Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S . Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2001; 1(6):489-95. DOI: 10.1038/82732. View

Sun X, Yin J, Starovasnik M, Fairbrother W, Dixit V . Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem. 2001; 277(11):9505-11. DOI: 10.1074/jbc.M109488200. View

Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H . Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003; 301(5633):640-3. DOI: 10.1126/science.1087262. View

10.

Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim S . Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature. 2003; 424(6950):743-8. DOI: 10.1038/nature01889. View

11.

Wen L, Zhuang L, Luo X, Wei P . TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem. 2003; 278(40):39251-8. DOI: 10.1074/jbc.M305833200. View

12.

Micheau O, Tschopp J . Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003; 114(2):181-90. DOI: 10.1016/s0092-8674(03)00521-x. View

13.

Newton K, Sun X, Dixit V . Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol. 2004; 24(4):1464-9. PMC: 344190. DOI: 10.1128/MCB.24.4.1464-1469.2004. View

14.

Yang Y, Hu W, Feng S, Ma J, Wu M . RIP3 beta and RIP3 gamma, two novel splice variants of receptor-interacting protein 3 (RIP3), downregulate RIP3-induced apoptosis. Biochem Biophys Res Commun. 2005; 332(1):181-7. DOI: 10.1016/j.bbrc.2005.04.114. View

15.

Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N . Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2006; 1(2):112-9. DOI: 10.1038/nchembio711. View

16.

Siegel R . Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol. 2006; 6(4):308-17. DOI: 10.1038/nri1809. View

17.

Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P . RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 2007; 14(3):400-10. DOI: 10.1038/sj.cdd.4402085. View

18.

Mack C, Sickmann A, Lembo D, Brune W . Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein. Proc Natl Acad Sci U S A. 2008; 105(8):3094-9. PMC: 2268590. DOI: 10.1073/pnas.0800168105. View

19.

Kono H, Rock K . How dying cells alert the immune system to danger. Nat Rev Immunol. 2008; 8(4):279-89. PMC: 2763408. DOI: 10.1038/nri2215. View

20.

Degterev A, Hitomi J, Germscheid M, Chen I, Korkina O, Teng X . Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008; 4(5):313-21. PMC: 5434866. DOI: 10.1038/nchembio.83. View